nach oben

Erschienen in:

21.02.2019 | PRECLINICAL STUDIES

Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer

verfasst von: Juan Tang, Na Wang, JingBo Wu, PeiRong Ren, JunYang Li, LiShi Yang, XiangXiang Shi, Yue Chen, ShaoZhi Fu, Sheng Lin

Erschienen in: Investigational New Drugs | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Summary

The aim of this study was to explore the synergistic anti-tumor effects of cytarabine hyaluronic acid-tyramine (Ara-HA-Tyr) hydrogel conjugates and radiotherapy (RT) in the Lewis lung cancer (LLC) xenograft model, and the mechanisms involved. The radiotherapy sensitization ratio (SER) of 0.5 μg cytarabine (Ara-C) was 1.619 in the LLC cells. Ara-HA-Tyr was prepared by encapsulating Ara-C into hyaluronic acid-tyramine (HA-Tyr) conjugates. The hydrogels were formed through the oxidative coupling of tyramines by hydrogen peroxide (H₂O₂) and horseradish peroxidase (HRP). Mice engrafted with the LLC cells were given intra-tumoral injections of saline, Ara-C or Ara-HA-Tyr, with or without RT. The combination of Ara-HA-Tyr and RT increased survival compared to free Ara-C and RT (p < 0.05), and prolonged tumor growth delay (TGD). Furthermore, the RT + Ara-HA-Tyr combination therapy significantly reduced ¹⁸F-FDG uptake, induced cell cycle arrest at G2/M-phase, increased apoptosis and histone H2AX phosphorylation (γ-H2AX), and decreased the proliferation index (Ki67) in tumor cells compared to either monotherapy. Taken together, Ara-C encapsulated with HA-Tyr effectively sensitized tumor xenografts to RT and showed significantly less systemic toxicity.

Bernier J, Hall EJ, Giaccia A (2004) Radiation oncology: a century of achievements. Nat Rev Cancer 49:737–747. https://doi.org/10.1038/nrc1451 CrossRef

Linam J, Yang LX (2015) Recent developments in radiosensitization. Anticancer Res 355:2479–2485

Schiffer CA (2014) Optimal dose and schedule of consolidation in AML: is there a standard? Best Pract Res Clin Haematol 273-4:259–264. https://doi.org/10.1016/j.beha.2014.10.007 CrossRef

Rusch VW, Figlin R, Godwin D, Piantadosi S (1991) Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a lung Cancer study group trial. J Clin Oncol 92:313–319. https://doi.org/10.1200/jco.1991.9.2.313 CrossRef

Karami L, Jalili S (2015) Effects of cholesterol concentration on the interaction of cytarabine with lipid membranes: a molecular dynamics simulation study. J Biomol Struct Dyn 336:1254–1268. https://doi.org/10.1080/07391102.2014.941936 CrossRef

Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 92:301–309. https://doi.org/10.1517/14656566.9.2.301 CrossRef

Spriggs DR, Robbins G, Takvorian T et al (1985) Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study. Cancer Res 458:3932–3936

Liao YH, Jones SA, Forbes B, Martin GP, Brown MB (2005) Hyaluronan: pharmaceutical characterization and drug delivery. J Drug Deliv 126:327–342. https://doi.org/10.1080/10717540590952555 CrossRef

Wang J, Wang X, Cao Y, Huang T, Song D‑X, Tao H‑R (2018) Therapeutic potential of hyaluronic acid/chitosan nanoparticles for the delivery of curcuminoid in knee osteoarthritis and an in vitro evaluation in chondrocytes. Int J Mol Med. https://doi.org/10.3892/ijmm.2018.3817

10.

Lokeshwar VB, Mirza S, Jordan A (2014) Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res 123:35–65. https://doi.org/10.1016/b978-0-12-800092-2.00002-2 CrossRefPubMedPubMedCentral

11.

Lin WJ, Lee WC (2018) Polysaccharide-modified nanoparticles with intelligent CD44 receptor targeting ability for gene delivery. Int J Nanomedicine 13:3989–4002. https://doi.org/10.2147/ijn.s163149 CrossRefPubMedPubMedCentral

12.

Hatefi A, Amsden B (2002) Biodegradable injectable in situ forming drug delivery systems. J Control Release 801-3:9–28CrossRef

13.

Kretlow JD, Klouda L, Mikos AG (2007) Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev 594-5:263–273. https://doi.org/10.1016/j.addr.2007.03.013 CrossRef

14.

Kurisawa M, Chung JE, Yang YY, Gao SJ, Uyama H (2005) Injectable biodegradable hydrogels composed of hyaluronic acid-tyramine conjugates for drug delivery and tissue engineering. Chem Commun 34:4312–4314. https://doi.org/10.1039/b506989k CrossRef

15.

Lee F, Chung JE, Kurisawa M (2008) An injectable enzymatically crosslinked hyaluronic acid–tyramine hydrogel system with independent tuning of mechanical strength and gelation rate. J Soft Matter 44:880. https://doi.org/10.1039/b719557e CrossRef

16.

Koga K, Iizuka E, Sato A, Ekimoto H, Okada M (1995) Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice. Cancer Chemother Pharmacol 366:459–462. https://doi.org/10.1007/bf00685794 CrossRef

17.

Skrzypski M, Jassem J (2018) Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treat Rev 66:114–121. https://doi.org/10.1016/j.ctrv.2018.04.001 CrossRefPubMed

18.

Lawrence TS, Blackstock AW, McGinn C (2003) The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 131:13–21. https://doi.org/10.1053/srao.2003.50002 CrossRef

19.

Hirata N, Fujisawa Y, Tanabe K, Harada H, Hiraoka M, Nishimoto SI (2009) Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics. Org Biomol Chem 74:651–654. https://doi.org/10.1039/b816194a CrossRef

20.

Reese ND, Schiller GJ (2013) High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr Hematol Malig Rep 82:141–148. https://doi.org/10.1007/s11899-013-0156-3 CrossRef

21.

Ewald B, Sampath D, Plunkett W (2008) Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2750:6522–6537. https://doi.org/10.1038/onc.2008.316 CrossRef

22.

McGinn CJ, Lawrence TS (2001) Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 114:270–280CrossRef

23.

Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N (2018) Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, Pharmacodynamics and Metabolism. Cancers (Basel) 107:240. https://doi.org/10.3390/cancers10070240 CrossRef

24.

Lawrence TS, Chang EY, Hahn TM et al (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2’,2’-difluoro-2’-deoxycytidine (Gemcitabine). Clin Cancer Res 35:777–782

25.

Lee F, Chung JE, Kurisawa M (2009) An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. J Control Release 1343:186–193. https://doi.org/10.1016/j.jconrel.2008.11.028 CrossRef

26.

Huang G, Huang H (2018) Hyaluronic acid-based biopharmaceutical delivery and tumor-targeted drug delivery system. J Control Release 278:122–126. https://doi.org/10.1016/j.jconrel.2018.04.015 CrossRefPubMed

27.

Wu JL, Tian GX, Yu WJ, Jia GT, Sun TY, Gao ZQ (2016) pH-responsive hyaluronic acid-based mixed micelles for the hepatoma-targeting delivery of doxorubicin. Int J Mol Sci 174:364. https://doi.org/10.3390/ijms17040364 CrossRef

28.

Kim A, Checkla DM, Dehazya P et al (2003) Characterization of DNA-hyaluronan matrix for sustained gene transfer. J Control Release 901:81–95CrossRef

29.

Qin Y, Tian Y, Liu Y, Li D, Zhang H, Yang Y, Qi J, Wang H, Gan L (2018) Hyaluronic acid-modified cationic niosomes for ocular gene delivery: improving transfection efficiency in retinal pigment epithelium. J Pharm Pharmacol 709:1139–1151. https://doi.org/10.1111/jphp.12940 CrossRef

30.

Ogawa Y, Kubota K, Ue H et al (2009) Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-radiation therapy for Unresectable carcinomas, type II (KORTUC II). Int J Oncol 343:609–618

31.

Jordan AR, Racine RR, Hennig MJ et al (2015) The role of CD44 in disease pathophysiology and targeted treatment. Front Immunol 6:182. https://doi.org/10.3389/fimmu.2015.00182 CrossRefPubMedPubMedCentral

32.

Yang Y, Zhao Y, Lan J, Kang Y, Zhang T, Ding Y, Zhang X, Lu L (2018) Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery. Int J Nanomedicine 13:4361–4378. https://doi.org/10.2147/ijn.s165359 CrossRefPubMedPubMedCentral

33.

Yoon HY, Koo H, Choi KY, Lee SJ, Kim K, Kwon IC, Leary JF, Park K, Yuk SH, Park JH, Choi K (2012) Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 3315:3980–3989. https://doi.org/10.1016/j.biomaterials.2012.02.016 CrossRef

34.

Xiong H, Ni J, Jiang Z, Tian F, Zhou J, Yao J (2018) Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin. Biomater Sci 69:2527–2540. https://doi.org/10.1039/c8bm00570b CrossRef

35.

Saravanakumar G, Choi KY, Yoon HY, Kim K, Park JH, Kwon IC, Park K (2010) Hydrotropic hyaluronic acid conjugates: synthesis, characterization, and implications as a carrier of paclitaxel. Int J Pharm 3941-2:154–161. https://doi.org/10.1016/j.ijpharm.2010.04.041 CrossRef

36.

Zhao T, He Y, Chen H, Bai Y, Hu W, Zhang L (2017) Novel apigenin-loaded sodium hyaluronate nano-assemblies for targeting tumor cells. Carbohydr Polym 177:415–423. https://doi.org/10.1016/j.carbpol.2017.09.007 CrossRefPubMed

37.

Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 185:330–337. https://doi.org/10.1016/j.semcancer.2008.03.011 CrossRef

38.

Shewach DS, Lawrence TS (2007) Antimetabolite radiosensitizers. J Clin Oncol 2526:4043–4050. https://doi.org/10.1200/jco.2007.11.5287 CrossRef

39.

Sarkisjan D, van den Berg J, Smit E, Lee YB, Kim DJ, Peters GJ (2016) The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines. Nucleosides Nucleotides Nucleic Acids 3510-12:619–630. https://doi.org/10.1080/15257770.2016.1216565 CrossRef

40.

Heyer WD, Ehmsen KT, Liu J (2010) Regulation of homologous recombination in eukaryotes. Annu Rev Genet 44:113–139. https://doi.org/10.1146/annurev-genet-051710-150955 CrossRefPubMedPubMedCentral

41.

Magin S, Papaioannou M, Saha J, Staudt C, Iliakis G (2015) Inhibition of homologous recombination and promotion of mutagenic repair of DNA double-Strand breaks underpins Arabinoside-nucleoside analogue Radiosensitization. Mol Cancer Ther 146:1424–1433. https://doi.org/10.1158/1535-7163.mct-14-0682 CrossRef

42.

Thiemann M, Oertel S, Ehemann V et al (2012) In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Radiat Oncol 7:52. https://doi.org/10.1186/1748-717x-7-52 CrossRefPubMedPubMedCentral

43.

Nickoloff JA (2017) Paths from DNA damage and signaling to genome rearrangements via homologous recombination. Mutat Res 806:64–74. https://doi.org/10.1016/j.mrfmmm.2017.07.008 CrossRefPubMed

Titel: Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer
verfasst von: Juan Tang
Na Wang
JingBo Wu
PeiRong Ren
JunYang Li
LiShi Yang
XiangXiang Shi
Yue Chen
ShaoZhi Fu
Sheng Lin
Publikationsdatum: 21.02.2019
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 6/2019
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-019-00740-4

Springer Medizin

Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage

Delineation of proapoptotic signaling of anthracene-shelled M2L4 metallacapsules and their synergistic activity with curcumin in cisplatin-sensitive and resistant tumor cell lines

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells

GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma

A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie